CRISPR: Move Beyond Differences
By Charis Thompson,
Nature
| 06. 24. 2015
Untitled Document
This autumn, researchers and other experts will come together to discuss the scientific, ethical and policy issues associated with gene-editing research in humans. Plans for the international meeting were announced by the US National Academy of Sciences and the National Academy of Medicine after a study was published in which researchers used a gene-editing tool known as CRISPR to modify the genomes of non-viable human embryos1.
Whether this meeting and others like it, planned in the United States, can help to forge a path for gene editing that takes into account all the relevant needs and concerns will depend on what efforts are made to integrate the diverse perspectives of people with different expertise and values. A first step to such integration is understanding how different perspectives arise.
One division in cares and concerns seems at times to fall along stereotypical gender lines. This was powerfully demonstrated during a meeting in Atlanta, Georgia, last month on biotechnology and ethics. About 200 global thought leaders gathered at BEINGS 2015 to “reach consensus on the direction of biotechnology...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...